3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Neoplasms
5
Multiple Myeloma
3
Hematologic Neoplasms
3
Thyroid Cancer, Papillary
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Melanoma
2
Lymphoma, Non-Hodgkin
2
Erdheim-Chester Disease
2
Carcinoma, Non-Small-Cell Lung
2
Xanthogranuloma, Juvenile
1
Thyroid Carcinoma, Anaplastic
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoproliferative Disorders
1
Laryngeal Neoplasms
1
Histiocytosis, Sinus
1
Histiocytosis, Langerhans-Cell
1
Histiocytic Sarcoma
1
Histiocytic Disorders, Malignant
1
Glioma
1
Colorectal Neoplasms
1
Adenocarcinoma, Follicular
1
Interventions
trametinib
3
dabrafenib
3
zimberelimab
1
sacituzumab govitecan
1
pembrolizumab
1
lenvatinib
1
cobimetinib
1
cemiplimab
1
Vemurafenib
1
Radiotherapy, Intensity-Modulated
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Thyroid Carcinoma, Anaplastic
×
cobimetinib
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled